137 related articles for article (PubMed ID: 18223690)
1. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Miyamoto D; Miyamoto M; Takahashi A; Yomogita Y; Higashi H; Kondo S; Hatakeyama M
Oncogene; 2008 Jun; 27(25):3508-15. PubMed ID: 18223690
[TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
Matozaki T; Murata Y; Saito Y; Okazawa H; Ohnishi H
Cancer Sci; 2009 Oct; 100(10):1786-93. PubMed ID: 19622105
[TBL] [Abstract][Full Text] [Related]
3. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
4. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y
Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851
[TBL] [Abstract][Full Text] [Related]
5. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.
Yamamoto T; Isomura M; Xu Y; Liang J; Yagasaki H; Kamachi Y; Kudo K; Kiyoi H; Naoe T; Kojma S
Leuk Res; 2006 Sep; 30(9):1085-9. PubMed ID: 16533526
[TBL] [Abstract][Full Text] [Related]
6. The tyrosine phosphatase Shp2 (PTPN11) in cancer.
Chan G; Kalaitzidis D; Neel BG
Cancer Metastasis Rev; 2008 Jun; 27(2):179-92. PubMed ID: 18286234
[TBL] [Abstract][Full Text] [Related]
7. Cell surface expression of channel catfish leukocyte immune-type receptors (IpLITRs) and recruitment of both Src homology 2 domain-containing protein tyrosine phosphatase (SHP)-1 and SHP-2.
Montgomery BC; Mewes J; Davidson C; Burshtyn DN; Stafford JL
Dev Comp Immunol; 2009 Apr; 33(4):570-82. PubMed ID: 19013191
[TBL] [Abstract][Full Text] [Related]
8. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional effects of disease-causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP-2.
Bocchinfuso G; Stella L; Martinelli S; Flex E; Carta C; Pantaleoni F; Pispisa B; Venanzi M; Tartaglia M; Palleschi A
Proteins; 2007 Mar; 66(4):963-74. PubMed ID: 17177198
[TBL] [Abstract][Full Text] [Related]
10. Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
Mutesa L; Pierquin G; Janin N; Segers K; Thomée C; Provenzi M; Bours V
Cancer Genet Cytogenet; 2008 Apr; 182(1):40-2. PubMed ID: 18328949
[TBL] [Abstract][Full Text] [Related]
11. Germline KRAS mutations cause Noonan syndrome.
Schubbert S; Zenker M; Rowe SL; Böll S; Klein C; Bollag G; van der Burgt I; Musante L; Kalscheuer V; Wehner LE; Nguyen H; West B; Zhang KY; Sistermans E; Rauch A; Niemeyer CM; Shannon K; Kratz CP
Nat Genet; 2006 Mar; 38(3):331-6. PubMed ID: 16474405
[TBL] [Abstract][Full Text] [Related]
12. Germline gain-of-function mutations in SOS1 cause Noonan syndrome.
Roberts AE; Araki T; Swanson KD; Montgomery KT; Schiripo TA; Joshi VA; Li L; Yassin Y; Tamburino AM; Neel BG; Kucherlapati RS
Nat Genet; 2007 Jan; 39(1):70-4. PubMed ID: 17143285
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2.
Zhang RY; Yu ZH; Chen L; Walls CD; Zhang S; Wu L; Zhang ZY
J Biol Chem; 2020 May; 295(18):6187-6201. PubMed ID: 32188694
[TBL] [Abstract][Full Text] [Related]
14. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Ohnishi N; Yuasa H; Tanaka S; Sawa H; Miura M; Matsui A; Higashi H; Musashi M; Iwabuchi K; Suzuki M; Yamada G; Azuma T; Hatakeyama M
Proc Natl Acad Sci U S A; 2008 Jan; 105(3):1003-8. PubMed ID: 18192401
[TBL] [Abstract][Full Text] [Related]
15. SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration.
Yo K; Iwata S; Hashizume Y; Kondo S; Nomura S; Hosono O; Kawasaki H; Tanaka H; Dang NH; Morimoto C
Biochem Biophys Res Commun; 2009 Apr; 382(1):210-4. PubMed ID: 19275884
[TBL] [Abstract][Full Text] [Related]
16. Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
Binder G
Horm Res; 2009 Apr; 71 Suppl 2():64-70. PubMed ID: 19407499
[TBL] [Abstract][Full Text] [Related]
17. 2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.
Geronikaki A; Eleftheriou P; Vicini P; Alam I; Dixit A; Saxena AK
J Med Chem; 2008 Sep; 51(17):5221-8. PubMed ID: 18702480
[TBL] [Abstract][Full Text] [Related]
18. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.
Zhan Y; Counelis GJ; O'Rourke DM
Exp Cell Res; 2009 Aug; 315(14):2343-57. PubMed ID: 19427850
[TBL] [Abstract][Full Text] [Related]
19. Mutations of PTPN11 are rare in adult myeloid malignancies.
Hugues L; Cavé H; Philippe N; Pereira S; Fenaux P; Preudhomme C
Haematologica; 2005 Jun; 90(6):853-4. PubMed ID: 15951301
[TBL] [Abstract][Full Text] [Related]
20. Pilocytic astrocytoma in a child with Noonan syndrome.
Schuettpelz LG; McDonald S; Whitesell K; Desruisseau DM; Grange DK; Gurnett CA; Wilson DB
Pediatr Blood Cancer; 2009 Dec; 53(6):1147-9. PubMed ID: 19621452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
